CRISPR Therapeutics Q4 2025 net loss $130.6M; CASGEVY Q4 revenue $54M, full year $116M

CRISPR Therapeutics AG

2025-FY EPS reported -$6.47 revenue$3,510,000

Net loss of $130.6M in Q4 2025 vs $37.3M loss in Q4 2024; collaboration expense increased to $53.7M.
CASGEVY revenue $54M in Q4, $116M full year 2025; 64 patients infused during the year (30 in Q4).
Cash, cash equivalents and marketable securities $1,975.8M as of Dec 31, 2025, vs $1,903.8M Dec 31, 2024.
R&D expenses $83.5M (Q4 2025) vs $71.7M (Q4 2024); G&A $18.4M vs $18.1M.
Pediatric CASGEVY submissions for ages 5-11 expected H1 2026; in vivo programs CTX460 (mid-2026) and CTX340 (H1 2026) to enter clinic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.